One Genentech abstract at ASCO pertaining to naked T-DM1 treatment clearly showed that participants that over-expressed Her2+ benefitted more from this treatment than her2+ normal candidates. Stronger results were reported in both progression free survival time as well in operational response.
http://www.medpagetoday.com/MeetingCoverage/ASCO/20498"